Trial Profile

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5245 for the Treatment of COVID-19 in Nonhospitalized Participants

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 27 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Obeldesivir (Primary)
Indications SARS-CoV-2 acute respiratory disease
Focus Adverse reactions; Registrational; Therapeutic Use
Acronyms OAKTREE
Sponsors Gilead Sciences

Most Recent Events

09 Oct 2024 According to Gilead science media release, data from this study will be presented at IDWeek 2024, taking place from October 16-19.
06 Feb 2024 Primary endpoint (Time to Coronavirus Disease 2019 (COVID-19) Symptom Alleviation by Day 29) has not been met.
05 Feb 2024 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com